Advancing Nuclear Medicine Through Innovation (2007)

The committee organized several meetings to obtain information about the state of the science of nuclear medicine. The committee held five data-gathering sessions open to the public to receive briefings from technical experts, federal agencies, and other interested parties. The written materials (e.g., PowerPoint presentations and written statements) obtained by the committee at these open sessions are posted on the Web site for this project: http://www8.nationalacademies.org/cp/projectview.aspx?key=48654.

The objective of this meeting was to obtain background information on the study request. The committee was briefed by both sponsors, the Department of Energy (DOE) and the National Institutes of Health (NIH), and by five professional organizations with an interest in nuclear medicine. The following is the list of topics and speakers for the open session:

• Mission of DOE’s Isotope Program, John Pantaleo, M.S., Program Director, Isotope Programs, Office of Nuclear Energy, DOE

• DOE Support of Nuclear Medicine Research, Michael Viola, M.D., Director, Life and Medical Sciences Division, Biological and Environmental Research, Office of Science, DOE

• NIH and National Cancer Institute (NCI) Perspectives on Nuclear Medicine Research, Daniel Sullivan, M.D., Cancer Imaging Program, NCI, NIH

• National Institute of Biomedical Imaging and Bioengineering (NIBIB) Perspective on the National Academies “State of the Science in Nuclear Medicine” Study, William Heetderks, M.D., Associate Director for Extramural Science Programs, NIBIB, NIH

• Presentation to NAS Committee on “State of the Science in Nuclear Medicine,” Michael Welch, Ph.D., Professor of Radiology, Washington University School of Medicine, on behalf of the Society of Nuclear Medicine

• Society of Radiopharmaceutical Sciences, William Eckelman, Ph.D., Adjunct Professor of Radiology, University of California at San Diego, on behalf of the Society of Radiopharmaceutical Sciences

• State of the Science in Nuclear Medicine: IEEE Perspective, William Moses, Ph.D., Senior Staff Scientist in the Life Sciences Division at Lawrence Berkeley National Laboratory, on behalf of the IEEE Nuclear & Plasma Sciences Society

• Issues Affecting the Future of Nuclear Medicine, Roy Brown, Senior Director, Federal Affairs, Council on Radionuclides and Radiopharmaceuticals

• Perspectives from the Society of Molecular Imaging, Thomas Budinger, M.D., Ph.D., Professor of Radiology, University of California at San Francisco, on behalf of the Society of Molecular Imaging

• State of the Science in Nuclear Medicine: A Physician-Scientist’s Perspective, Richard Wahl, M.D., Henry N. Wagner, Jr., Professor of Nuclear Medicine, Johns Hopkins University, on behalf of the Academy of Radiology Research

The objective of the second meeting was to gather information on the state of the science in radiopharmaceuticals and issues surrounding isotope availability to the nuclear medicine community (charges 1 and 3 of the statement of task). The following is the list of topics and speakers who presented during the open session:

• NCI’s Current and Future Commitment to Translational Research: an Interim Report of the Translational Research Working Group, Ernest Hawk, M.D., M.P.H., Director of the Office of Centers, Training, & Resources in the Office of the Director, NCI, NIH

• Radiopharmaceutical Chemistry: Future Needs and Directions, Michael Welch, Ph.D., Professor of Radiology, Molecular Biology and Pharmacology, and Biomedical Engineering, and Co-Director of the Division of Radiological Sciences, Washington University Medical School

• Supporting the Nation’s Nuclear Medicine Research, Ralph Butler, M.S., Director, and Alan Ketring, Ph.D., Associate Director of the Radiopharmaceutical R&D Program, University of Missouri Research Reactor

• Radiolabeled Therapeutic Monoclonal Antibodies, Martin Brechbiel, Ph.D., Chief of the Radioimmune and Inorganic Chemistry Section, NCI, NIH

• Future Needs for Radiopharmaceutical Development for the Diagnosis and Treatment of Human Disease, Hank Kung, Ph.D., Professor of Radiology and Pharmacology, University of Pennsylvania

• National Academies’ Meeting: Committee on State of the Science of Nuclear Medicine, Cynthia Flannery, M.S., Team Leader of the Medical Radiation Safety Team, Nuclear Regulatory Commission

The objective of the third meeting was to gather information on issues surrounding training of personnel in nuclear medicine (charge 4). The following is the list of panelists for the open session:

• Paul DeLuca, Ph.D., Associate Dean for Research & Graduate Studies, University of Wisconsin

• Claude Meares, Ph.D., Professor of Chemistry, University of California at Davis

• Mark Green, Ph.D., Professor and Head of the Division of Nuclear Pharmacy Department of Industrial and Physical Pharmacy, School of Pharmacy and Pharmaceutical Sciences Purdue University

• Greggory Choppin, Ph.D., Senior Scientist & Project Director, Florida State University

• Jeffrey Norenberg, Ph.D., Associate Director, New Mexico Center for Isotopes in Medicine, University of New Mexico

• Michael Graham, M.D., Ph.D., Professor, Department of Radiology, University of Iowa, for American College of Radiology

• Ken Miller, M.S., Professor of Radiology & Director in Medicine, Pennsylvania State University, for Health Physics Society

• Sabee Molloi, Ph.D., Professor, Radiological Sciences, University of California at Irvine, for American Association of Physicists in Medicine

• William Jagust, M.D., Professor of Neurology, University of California at Berkeley, for American Academy of Neurology

• Ward Digby, Ph.D., Director, Siemens

• Ludger Dinkelborg, Ph.D., Head of PET Research, Schering AG

• Bernard Fine, M.D., Ph.D., Genentech

The objective of the fourth meeting was to gather information on future needs, instrumentation and computational needs (charge 2), targeted radionuclide therapy, and future technologies applicable to nuclear medicine. The following is the list of speakers for the open session:

• Imaging in the Brain Sciences 2006,Marcus Raichle, M.D., Professor of Radiology, Neurology, Neurobiology, Biomedical Engineering and Psychology and co-Director, Division of Radiological Sciences, Washington University School of Medicine

• State of the Science in Nuclear Medicine, Markus Schwaiger, M.D., Professor & Director, Department of Nuclear Medicine, Technical University of Munich

• Need a New Discovery Pathway for Molecular Imaging Bio and Surrogate Markers, Michael Phelps, M.D., Ph.D., Chair of Department of Molecular and Medical Pharmacology, Director of Crump Institute for Molecular Imaging, and Director of the Institute of Molecular Medicine, University of California at Los Angeles

• The Future of Nuclear Medicine at the DOE Laboratories, Stephen Derenzo, Ph.D., Senior Staff Scientist, Lawrence Berkeley National Laboratory

• SPECT and SPECT/CT Instrumentation and Computation, Bruce Hasegawa, Ph.D., Professor of Radiology, University of California at San Francisco

• Nuclear Medicine Preclinical Instrumentation Technologies: microPET and Beyond, Arion Chatziioannou, Ph.D., Assistant Professor, Department of Molecular & Medical Pharamacology, University of California at Los Angeles

• Instrumentation and Computation: Role of Modeling and Computation in Nuclear Medicine, Sung-Cheng Huang, Ph.D., Professor, Department of Molecular & Medical Pharamacology and Department of Biomathematics, University of California at Los Angeles

• Siemens Molecular Imaging, Bernard Bendriem, Ph.D., Vice President, Science & Technology, Siemens

• Susan Knox, M.D., Associate Professor, Department of Radiation Oncology, Stanford University

• David Goldenberg, M.D., Sc.D., President, Garden State Cancer Center

• Mark Kaminski, M.D., Professor, Department of Internal Medicine, Director of the Leukemia/Lymphoma Program, University of Michigan

• Alexander McEwan, M.D., Nuclear Medicine Physician and Di-

rector of Oncologic Imaging at Cross Cancer Institute, and Director of Division of Oncologic Imaging, Department of Oncology, University of Alberta

• Andrew Raubitschek, M.D., Chair, City of Hope National Medical Center

• Peter Carroll, M.D., Co-Director of Urologic Oncology Service, and Chair of Urology Department, University of California at San Francisco

• Keith McCormick, M.B.A., Senior Manager, Oncology Marketing, Biogen-IDEC

• Combining In Vitro and In Vivo Diagnostics via a Systems Biology Foundation, James Heath, Ph.D., Professor of Chemistry, California Institute of Technology

• Micro- and Nanotechnologies for Accelerated Access to Biological Information, Michael Ramsey, Ph.D., Minnie N. Goldby Distinguished Professor of Chemistry Chair, University of North Carolina

• Biological Large Scale Integration, Stephen Quake, Ph.D., Professor of Bioengineering, Stanford University

The objective of the fifth meeting was to gather information on further sponsor perspective and regulatory hurdles facing the field of nuclear medicine. The following is the list of speakers for the open session:

• Michael Viola, M.D., Director, Life and Medicine Sciences Division, DOE

• John Pantaleo, M.S., Director, Isotope Programs, DOE

• Belinda Seto, Ph.D., Deputy Director, NIBIB, NIH

• George Mills, M.D., Director, Division of Medical Imaging & Hematology Products, Food and Drug Administration

The objective of the sixth meeting was to gather information on developments at the DOE-Nuclear Energy’s Isotope Programs. The following is the list of speakers for the open session:

• John Pantaleo, M.S., Director, Isotope Programs, DOE

• Darrell Fisher, Ph.D., Scientific Director, Pacific Northwest National Laboratory